Ketalar 10mg/ml Injection/Infusion * Pharmacy Only: Prescription
Company:
Pfizer Healthcare IrelandStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 20 April 2021
File name
DEC202126186_Reg SPC KE 31_0 10mg per ml IE clean_1618920157.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 20 April 2021
File name
DEC202126186_Reg PIL KE 29_0 IE clean_1618920095.pdf
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 4 - how to report a side effect
- Change to section 6 - what the product contains
- Change to section 6 - date of revision
Updated on 10 November 2020
File name
DEC202074561_Reg SPC KE 29_0 10mg per ml IE_1604994477.pdf
Reasons for updating
- Change to section 6.4 - Special precautions for storage
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
Update to Section 6.4 Special precautions for storage as follows:
Addition of "This medicinal product does not require any special temperature storage conditions. Store in the original container".
Removal of "Do not store above 25 °C."
Updated on 10 November 2020
File name
DEC202074561_Reg PIL KE 26_0 IE_1604994425.pdf
Reasons for updating
- Change to section 5 - how to store or dispose
- Change to section 6 - date of revision
- Change to information for healthcare professionals
Updated on 10 June 2020
File name
DEC202038215_Reg SPC KE 28_2 10mg per ml IE_1591782582.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.2 - Pharmacokinetic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 10 June 2020
File name
DEC202038215_Reg PIL KE 25_1 IE_1591782522.pdf
Reasons for updating
- Change to section 6 - date of revision
Updated on 24 December 2019
File name
DEC201972910_Reg SPC KE 27_1 10mg per ml IE_clean_1577173408.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
|
The SPC has been updated as follows: Addition of adverse drug reactions (ADRs); acute kidney injury, hydronephrosis and ureteral disorders to section 4.4 Special warnings and precautions - Long-Term Use.
Text addition “Adverse effects have also been reported: see “Long-Term Use”. to section 4.4 Special warnings and precautions - Drug Abuse and Dependence. the term ‘micro’ is utilised instead of the symbol μ to denote terms of strength or dosing. |
Updated on 12 March 2019
File name
DEC201912384_clean Reg SPC KE 26_2 10mg per ml IE_1_1552401164.pdf
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
- Change to section 5.3 - Preclinical safety data
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 30 July 2018
File name
Reg PIL KE 23_1 IE clean_1532963103.pdf
Reasons for updating
- Change to section 6 - date of revision
- Change to information for healthcare professionals
Updated on 20 March 2018
File name
PIL_8710_356.pdf
Reasons for updating
- New PIL for new product
Updated on 19 March 2018
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 19 March 2018
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
|
The SPC has been updated as follows: Update to s4.5 in line with CDS update (regarding concurrent use of ketamine with diazepam). |
Updated on 19 March 2018
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Free text change information supplied by the pharmaceutical company
|
The SPC has been updated as follows: Update to s4.5 in line with CDS update (regarding concurrent use of ketamine with diazepam). |
Updated on 06 December 2017
Reasons for updating
- Change to section 4.1 - Therapeutic indications
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
Addition of “Ketamine is indicated in children and in adults” in section 4.1.Updated on 06 December 2017
Reasons for updating
- Change to section 4.1 - Therapeutic indications
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
Addition of “Ketamine is indicated in children and in adults” in section 4.1.Updated on 17 January 2017
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.3 - Shelf life
- Change to section 6.6 - Special precautions for disposal and other handling
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
Section 2 (10 mg/ml only) – correction to amount of sodium
Section 4.4 – text regarding use with caution in the chronic alcoholic and the alcohol-intoxicated patient reinstated
Section 6.3 – updated with text regarding use immediately unless method of opening precludes risk of microbial contamination
Section 6.6 – updated with text regarding use immediately unless method of opening precludes risk of microbial contamination; parenteral drugs should be inspected visually for particulate matter and discolorationUpdated on 17 January 2017
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.3 - Shelf life
- Change to section 6.6 - Special precautions for disposal and other handling
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
Section 2 (10 mg/ml only) – correction to amount of sodium
Section 4.4 – text regarding use with caution in the chronic alcoholic and the alcohol-intoxicated patient reinstated
Section 6.3 – updated with text regarding use immediately unless method of opening precludes risk of microbial contamination
Section 6.6 – updated with text regarding use immediately unless method of opening precludes risk of microbial contamination; parenteral drugs should be inspected visually for particulate matter and discolorationUpdated on 05 December 2016
Reasons for updating
- Change to section 5.3 - Preclinical safety data
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
Section 5.3 – addition of findings from animal researchUpdated on 05 December 2016
Reasons for updating
- Change to section 5.3 - Preclinical safety data
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
Section 5.3 – addition of findings from animal researchUpdated on 31 October 2016
Reasons for updating
- Change to section 6.4 - Special precautions for storage
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
|
The SPC has been updated as follows: Sec 6.4 Special precautions for storage was updated with the temperature storage conditions. |
|
The PIL has been updated to reflect the SmPC changes. Section 5 of the PIL was updated with temperature storage conditions. Corresponding SmPC section of the HCP part was also updated. See PIL tick list for sections updated. |
Updated on 31 October 2016
Reasons for updating
- Change to section 6.4 - Special precautions for storage
Free text change information supplied by the pharmaceutical company
|
The SPC has been updated as follows: Sec 6.4 Special precautions for storage was updated with the temperature storage conditions. |
|
The PIL has been updated to reflect the SmPC changes. Section 5 of the PIL was updated with temperature storage conditions. Corresponding SmPC section of the HCP part was also updated. See PIL tick list for sections updated. |
Updated on 28 October 2016
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.6 - Pregnancy and lactation
- Change to section 5.2 - Pharmacokinetic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
Sec 4.2 Dosage in Obstetrics and Maintenance of anaesthesia- to provide information that there is no substantive clinical information available on the optimal dose of ketamine when used intramuscularly or as a maintenance IV infusion during labour and delivery
Sec 4.6 Pregnancy - to provide information that there is no substantive clinical information available on the optimal dose of ketamine when used intramuscularly or as a maintenance IV infusion during labour and delivery and section
Sec 5.2 Distribution and Biotransformation - to provide updated information on ketamine distribution and additional information regarding the distribution of ketamine in the parturient populationUpdated on 28 October 2016
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.6 - Pregnancy and lactation
- Change to section 5.2 - Pharmacokinetic properties
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
Sec 4.2 Dosage in Obstetrics and Maintenance of anaesthesia- to provide information that there is no substantive clinical information available on the optimal dose of ketamine when used intramuscularly or as a maintenance IV infusion during labour and delivery
Sec 4.6 Pregnancy - to provide information that there is no substantive clinical information available on the optimal dose of ketamine when used intramuscularly or as a maintenance IV infusion during labour and delivery and section
Sec 5.2 Distribution and Biotransformation - to provide updated information on ketamine distribution and additional information regarding the distribution of ketamine in the parturient populationUpdated on 17 June 2016
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
section 6.5 is updated to reflect a change in vial size
Updated on 17 June 2016
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Free text change information supplied by the pharmaceutical company
section 6.5 is updated to reflect a change in vial size
Updated on 01 April 2015
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.6 - Pregnancy and lactation
- Change to section 5.2 - Pharmacokinetic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.2 – Section added with Dosage in obstetrics
Section 4.6 – Addition of Pregnancy wording and Lactation
Section 5.2 – Distribution details for peak plasma level
Updated on 01 April 2015
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.6 - Pregnancy and lactation
- Change to section 5.2 - Pharmacokinetic properties
Free text change information supplied by the pharmaceutical company
Section 4.2 – Section added with Dosage in obstetrics
Section 4.6 – Addition of Pregnancy wording and Lactation
Section 5.2 – Distribution details for peak plasma level
Updated on 23 October 2014
Reasons for updating
- Change to section 8 - MA number
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4 - Clinical particulars
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.1 - List of excipients
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows
Section 2- 4.3 Updated in line with QRD version 9
Section 4.4 Special Warnings and precautions for use- addition of hepatotoxicity language under the subheadings of ‘Long-term Use’ and ‘Drug Abuse and Dependence’.
Section 4.5 Interaction with other medicinal products and other forms of interaction- addition of Drug Drug Interactions
Section 4.6 and 4.7- Updated in line with QRD version 9
Section 4.8 Undesirable effects- addition of new ADR term ‘Drug-induced liver injury’ under MedDRA SOC ‘Hepatobiliary disorders’ accompanied with a footnote indicating an association with ‘extended period use (>3 days) or drug abuse.
Section 5.2 Pharmacokinetic properties- addition additional information regarding interactions with CYP P450 enzymes.
Section 5.3,6.1, 6..3, 6.4, 6.5, 6.6, 8-Updated in line with QRD version 9Updated on 23 October 2014
Reasons for updating
- Change to section 8 - MA number
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4 - Clinical particulars
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.1 - List of excipients
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows
Section 2- 4.3 Updated in line with QRD version 9
Section 4.4 Special Warnings and precautions for use- addition of hepatotoxicity language under the subheadings of ‘Long-term Use’ and ‘Drug Abuse and Dependence’.
Section 4.5 Interaction with other medicinal products and other forms of interaction- addition of Drug Drug Interactions
Section 4.6 and 4.7- Updated in line with QRD version 9
Section 4.8 Undesirable effects- addition of new ADR term ‘Drug-induced liver injury’ under MedDRA SOC ‘Hepatobiliary disorders’ accompanied with a footnote indicating an association with ‘extended period use (>3 days) or drug abuse.
Section 5.2 Pharmacokinetic properties- addition additional information regarding interactions with CYP P450 enzymes.
Section 5.3,6.1, 6..3, 6.4, 6.5, 6.6, 8-Updated in line with QRD version 9Updated on 09 September 2014
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.1 - List of excipients
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 8 - MA number
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 2- 4.3 Updated in line with QRD version 9
Section 4.4 Special Warnings and precautions for use- addition of hepatotoxicity language under the subheadings of ‘Long-term Use’ and ‘Drug Abuse and Dependence’.
Section 4.5 Interaction with other medicinal products and other forms of interaction- addition of Drug Drug Interactions
Section 4.6 and 4.7- Updated in line with QRD version 9
Section 4.8 Undesirable effects- addition of new ADR term ‘Drug-induced liver injury’ under MedDRA SOC ‘Hepatobiliary disorders’ accompanied with a footnote indicating an association with ‘extended period use (>3 days) or drug abuse.
Section 5.2 Pharmacokinetic properties- addition additional information regarding interactions with CYP P450 enzymes.
Section 5.3,6.1, 6..3, 6.4, 6.5, 6.6, 8-Updated in line with QRD version 9Updated on 09 September 2014
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.1 - List of excipients
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 8 - MA number
Free text change information supplied by the pharmaceutical company
Section 2- 4.3 Updated in line with QRD version 9
Section 4.4 Special Warnings and precautions for use- addition of hepatotoxicity language under the subheadings of ‘Long-term Use’ and ‘Drug Abuse and Dependence’.
Section 4.5 Interaction with other medicinal products and other forms of interaction- addition of Drug Drug Interactions
Section 4.6 and 4.7- Updated in line with QRD version 9
Section 4.8 Undesirable effects- addition of new ADR term ‘Drug-induced liver injury’ under MedDRA SOC ‘Hepatobiliary disorders’ accompanied with a footnote indicating an association with ‘extended period use (>3 days) or drug abuse.
Section 5.2 Pharmacokinetic properties- addition additional information regarding interactions with CYP P450 enzymes.
Section 5.3,6.1, 6..3, 6.4, 6.5, 6.6, 8-Updated in line with QRD version 9Updated on 16 August 2013
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 6.5 - Nature and contents of container
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 2 Qualitative and Quantitative Composition: updated for consistency
Section 4.4 Special Warnings and Precautions for Use: addition of abnormal liver function tests
Section 4.8 Undesirable effects: addition of hepatic effects
Section 6.5 Nature and Contents of Containers: updated for consistency
Updated on 16 August 2013
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 6.5 - Nature and contents of container
Free text change information supplied by the pharmaceutical company
Section 2 Qualitative and Quantitative Composition: updated for consistency
Section 4.4 Special Warnings and Precautions for Use: addition of abnormal liver function tests
Section 4.8 Undesirable effects: addition of hepatic effects
Section 6.5 Nature and Contents of Containers: updated for consistency
Updated on 24 April 2012
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 24 April 2012
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Free text change information supplied by the pharmaceutical company
Updated on 10 August 2010
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Sections 4.3
(Contra-indications) and 5.2 (Pharmacokinetic Properties): typographical/minor
corrections
Section 6.3 (Shelf
Life): substantial change
Section 6.4 (Special
Precautions for Storage): substantial changes
Updated on 10 August 2010
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
Free text change information supplied by the pharmaceutical company
Sections 4.3
(Contra-indications) and 5.2 (Pharmacokinetic Properties): typographical/minor
corrections
Section 6.3 (Shelf
Life): substantial change
Section 6.4 (Special
Precautions for Storage): substantial changes
Updated on 21 May 2010
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.1 - List of excipients
- Change to section 6.2 - Incompatibilities
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - MA number
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
1, 2, 4.2, 4.4, 4.5, 4.8, 5.1, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 7, 8, 9 and (as a consequence) 10.
Updated on 21 May 2010
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.1 - List of excipients
- Change to section 6.2 - Incompatibilities
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - MA number
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
1, 2, 4.2, 4.4, 4.5, 4.8, 5.1, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 7, 8, 9 and (as a consequence) 10.
Updated on 15 May 2009
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.3 - Text amendment: "See Adverse Reactions section" changed to "See section 4.8 Undesirable effects".
Section 4.4 - Information added regarding psychological manifestations, warnings for patients with respiratory problems and warnings for patients with liver problems.
Section 4.5 - Information added regarding bradycardia, hypotension, decreased cardiac output, respiratory depression, tachycardia and seizures.
Section 4.8 - Information added regarding immune system disorders, increased salivation, eye disorders and cardiac & vascular disorders.
Section 5.1 - Information added regarding 'Mechanism of Action'.
Section 5.2 - Information added regarding distribution and metabolism.
Updated on 15 May 2009
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 4.8 - Undesirable effects
Free text change information supplied by the pharmaceutical company
Section 4.3 - Text amendment: "See Adverse Reactions section" changed to "See section 4.8 Undesirable effects".
Section 4.4 - Information added regarding psychological manifestations, warnings for patients with respiratory problems and warnings for patients with liver problems.
Section 4.5 - Information added regarding bradycardia, hypotension, decreased cardiac output, respiratory depression, tachycardia and seizures.
Section 4.8 - Information added regarding immune system disorders, increased salivation, eye disorders and cardiac & vascular disorders.
Section 5.1 - Information added regarding 'Mechanism of Action'.
Section 5.2 - Information added regarding distribution and metabolism.
Updated on 09 January 2006
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 7 - Marketing authorisation holder
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 09 January 2006
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 7 - Marketing authorisation holder
Updated on 17 February 2004
Reasons for updating
- Change to section 7 - Marketing authorisation holder
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 17 February 2004
Reasons for updating
- Change to section 7 - Marketing authorisation holder
Updated on 26 June 2003
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 26 June 2003
Reasons for updating
- New SPC for medicines.ie